BNTXBioNTech SEFinished
A Study to Investigate the Novel Agent BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Advanced Melanoma That Has Not Responded to Other Forms of Treatment
Melanoma Stage III · Melanoma Stage IV · Unresectable Melanoma
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 184 (final count)
- Started
- May 19, 2021
- Main results expected
- Jan 25, 2024
- Fully finished
- Nov 24, 2025
- Results posted
- Dec 15, 2025
What counts as success
The trial's main goal(s), called the “primary outcome.”
Arm 1: Objective Response Rate (ORR)
Measured over: Up to 24 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT04526899 · record last updated 2026-01-08 · checked 2026-11-09 15:47 UTC